Terapia de mantenimiento con inhibidores de PARP en cáncer de ovario: Un nuevo concepto para aumentar la supervivencia en la enfermedad recurrente

Previous Page

Next Page

Page Background

SOLO 2

Olaparib

RC/RP after Plat

Only germ

mutant

PFS

(investig-assessed)

295

germ. mutant

NOVA

Niraparib

RC/RP (< 2 cm)

after Plat

Mutant and no

mutant

PFS

(central review)

553

(203 g mutant)

ARIEL 3

Rucaparib

RC/RP after plat

Mutant and

non mutant

PFS

(investig-assessed)

594

(196 g mutant)

PARPi

Population

BRCA

Primary

endpoint

n

Maintenance with PARP inhibitors

Phase III studies: Design